First Western Trust Bank Purchases New Shares in Edwards Lifesciences Co. (NYSE:EW)

First Western Trust Bank acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 4th quarter, Holdings Channel reports. The firm acquired 5,120 shares of the medical research company’s stock, valued at approximately $390,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Nordea Investment Management AB grew its position in Edwards Lifesciences by 1,224.1% during the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after buying an additional 1,488,791 shares in the last quarter. Telos Capital Management Inc. grew its holdings in shares of Edwards Lifesciences by 158.2% during the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock worth $6,970,000 after purchasing an additional 56,000 shares in the last quarter. Arlington Trust Co LLC increased its position in shares of Edwards Lifesciences by 5,092.4% in the fourth quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after purchasing an additional 12,069 shares during the period. Versor Investments LP raised its stake in Edwards Lifesciences by 83.3% in the third quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after purchasing an additional 2,043 shares in the last quarter. Finally, HealthInvest Partners AB bought a new stake in Edwards Lifesciences during the fourth quarter worth about $1,587,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 2.7 %

Shares of NYSE:EW traded up $2.33 during mid-day trading on Thursday, reaching $87.42. 3,421,899 shares of the company’s stock were exchanged, compared to its average volume of 3,709,712. The firm has a market capitalization of $52.68 billion, a price-to-earnings ratio of 37.68, a PEG ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The business’s fifty day moving average price is $90.03 and its 200-day moving average price is $79.73. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. On average, research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 857 shares of the stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total transaction of $73,359.20. Following the completion of the sale, the vice president now directly owns 23,890 shares in the company, valued at approximately $2,044,984. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, SVP Robert W.A. Sellers sold 12,210 shares of Edwards Lifesciences stock in a transaction on Monday, February 12th. The shares were sold at an average price of $87.00, for a total value of $1,062,270.00. Following the completion of the sale, the senior vice president now directly owns 13,087 shares of the company’s stock, valued at $1,138,569. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 857 shares of the stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total transaction of $73,359.20. Following the transaction, the vice president now directly owns 23,890 shares in the company, valued at approximately $2,044,984. The disclosure for this sale can be found here. In the last 90 days, insiders sold 231,550 shares of company stock worth $20,384,302. 1.27% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on EW shares. Stifel Nicolaus boosted their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. Oppenheimer lifted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Mizuho upped their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.